Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
33%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
4
80%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (20.0%)
Phase 24 (80.0%)

Trials by Status

active_not_recruiting120%
completed360%
terminated120%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_2

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

NCT06119217
completedphase_2

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine

NCT02564146
terminatedphase_1

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

NCT04060342
completedphase_2

Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.

NCT02043730
completedphase_2

Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma

NCT02181634

Clinical Trials (5)

Showing 5 of 5 trials
NCT06119217Phase 2

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Active Not Recruiting
NCT02564146Phase 2

First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine

Completed
NCT04060342Phase 1

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Terminated
NCT02043730Phase 2

Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.

Completed
NCT02181634Phase 2

Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5